DKK1 and adenocarcinoma: The DKK1 RNAscope laboratory developed test is currently being applied as part of a phase 2 clinical study of DKN-01 in combination with tislelizumab to prospectively identify previously treated G/GEJ adenocarcinoma patients with elevated DKK1 tumoral expression, and as a retrospective analysis of first-line patients treated with DKN-01 in combination with tislelizumab and chemotherapy (NCT04363801).